H. Panitch

发表

Nuclear magnetic resonance imaging in multiple sclerosis

L. Kaufman, L. Crooks, D. Norman, 1983, Annals of neurology.

MRI predictors of early conversion to clinically definite MS in the CHAMPS placebo group

Michael Wall, J. Herbert, Jack H. Simon, 2002, Neurology.

Interferon beta-1b in secondary progressive MS

D. Paty, Aaron E Miller, B. Weinshenker, 2004, Neurology.

Randomized, comparative study of interferon β-1a treatment regimens in MS

D. Goodin, B. Weinshenker, David K.B. Li, 2002, Neurology.

Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis

R. Thisted, A. Achiron, T. Vollmer, 2006, Annals of neurology.

Treatment of steroid-unresponsive tumefactive demyelinating disease with plasma exchange.

H. Panitch, W. Pendlebury, Y. Mao-Draayer, 2002, Neurology.

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients

C. Bever, H. Panitch, O. Khan, 1996, Neurology.

Long-term effect of thymectomy plus prednisone versus prednisone alone in patients with non-thymomatous myasthenia gravis: 2-year extension of the MGTX randomised trial

A. Marx, S. Muley, R. Conwit, 2019, The Lancet Neurology.

Isometric Measurement of Hamstrings and Quadriceps Strength in Multiple Sclerosis Patients: Sensitivity and Variability

Gerald V. Smith, C. Bever, H. Panitch, 1995 .

Interferon β-lb reduces Interferon γ-induced antigen-presenting capacity of human glial and B cells

H. Panitch, Kenneth P. Johnson, S. Dhib-jalbut, 1995, Journal of Neuroimmunology.

Interferon beta-1b reduces interferon gamma-induced antigen-presenting capacity of human glial and B cells.

H. Panitch, S. Dhib-jalbut, R. Milo, 1995, Journal of neuroimmunology.

Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years

G. Barger, S. Reingold, C. Bever, 2000, Multiple sclerosis.

Lymphocytes from multiple sclerosis patients produce elevated levels of gamma interferonin vitro

R. Hirsch, H. Panitch, Kenneth P. Johnson, 1985, Journal of Clinical Immunology.

Progressive rubella panencephalitis. Late onset after congenital rubella.

J. Wolinsky, H. Panitch, N. Cremer, 1975, The New England journal of medicine.

Serial evoked potential studies in patients with definite multiple sclerosis. Clinical relevance.

M. Aminoff, S. Davis, H. Panitch, 1984, Archives of neurology.

Pathogenesis of visna. I. Sequential virologic, serologic, and pathologic studies.

H. Panitch, G. Georgsson, N. Nathanson, 1976, Laboratory investigation; a journal of technical methods and pathology.

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability. 1998 [classical article].

R. Schiffer, L. Weiner, J. Wolinsky, 2001, Neurology.

Intramedullary spinal cord abscess in a healthy woman

H. Panitch, A. Applebee, M. Ramundo, 2007, Neurology.

Clinical correlations of serial somatosensory evoked potentials in multiple sclerosis

M. Aminoff, H. Panitch, S. Davis, 1985, Neurology.

Interferon and Copolymer I Treatment in Multiple Sclerosis: Clinical and Pathobiological Implications

H. Panitch, Kenneth P. Johnson, K. Johnson, 1994 .

Glatiramer acetate blocks the activation of THP-1 cells by interferon-gamma.

C. Bever, H. Panitch, R. Milo, 1998, European journal of pharmacology.

Sulfogalactocerebroside and bis-(monoacylglyceryl)-phosphate as activators of spleen glucocerebrosidase.

J. Wherrett, H. Panitch, R. Glew, 1986, Clinica chimica acta; international journal of clinical chemistry.

Immunological studies of scrapie infection

S. Prusiner, D. Stites, H. Panitch, 1982, Journal of Neuroimmunology.

Monoclonal gammopathy and neuropathy

H. Weiner, D. Hafler, H. Panitch, 1986, Neurology.

Influence of infection on exacerbations of multiple sclerosis

H. Panitch, 2004, Annals of neurology.

Copolymer-l Review of its Pharmacological Properties and Therapeutic Potential in Multiple Sclerosis

A. Goonetilleke, H. Panitch, A. Coles, 1996 .

Pathogenesis of visna. III. Immune responses to central nervous system antigens in experimental allergic encephalomyelitis and visna.

H. Panitch, G. Georgsson, N. Nathanson, 1976, Laboratory investigation; a journal of technical methods and pathology.

Adoptive transfer of experimental allergic encephalomyelitis: requirement for macrophages in activation of spleen cells in vitro by concanavalin A or myelin basic protein.

H. Panitch, C. Ciccone, 1981, Cellular immunology.

Effect of combined IFNb-1a and glatiramer acetate therapy on GA-specific T-cell responses in multiple sclerosis

H. Panitch, S. Dhib-jalbut, K. Costello, 2002, Multiple sclerosis.

Copolymer 1 reduces relapse rate and improves disability in relapsing‐remitting multiple sclerosis

J. W. Rose, Jeffrey A. Cohen, R. Schiffer, 1995, Neurology.

Use of aggregating brain cultures to study the replication of herpes simplex virus types 1 and 2 in central nervous system tissue.

R. Dix, H. Panitch, L. Pulliam, 1984, Journal of virological methods.

Recurrent herpes simplex encephalitis: Recovery of virus after Ara‐A treatment

R. Dix, H. Panitch, J. Baringer, 1983, Annals of neurology.

Plasmapheresis in multiple sclerosis

H. Panitch, J. Petajan, Kenneth P. Johnson, 1980, Neurology.

Differential diagnosis of suspected multiple sclerosis: a consensus approach

Jeffrey A. Cohen, S. Reingold, M. Filippi, 2008, Multiple sclerosis.

The ultrastructure of early visna lesions

H. Panitch, G. Georgsson, N. Nathanson, 1977, Acta Neuropathologica.

Relapsing transverse myelitis

H. Panitch, P. Fishman, Dean S. Tippett, 1991, Neurology.

Upper respiratory tract infections trigger attacks of multiple sclerosis in patients treated with interferon

C. Bever, H. Panitch, Kenneth P. Johnson, 1991, Journal of Neuroimmunology.

Elevation of serum creatine phosphokinase in amyotrophic later a1 sclerosis

H. Panitch, G. Franklin, G. Franklin, 1972, Neurology.

Oral Agents for Relapsing–Remitting Multiple Sclerosis

H. Panitch, 2010 .

Treatment of multiple sclerosis with gamma interferon: Exacerbations associated with activation of the immune system

R. Hirsch, H. Panitch, Kenneth P. Johnson, 2011, Neurology.

EXACERBATIONS OF MULTIPLE SCLEROSIS IN PATIENTS TREATED WITH GAMMA INTERFERON

R. Hirsch, H. Panitch, Kenneth P. Johnson, 1987, The Lancet.

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial

P. Calabresi, M. Freedman, E. Waubant, 2009, Annals of neurology.

T8 antigen density on peripheral blood lymphocytes remains unchanged during exacerbations of multiple sclerosis

R. Hirsch, H. Panitch, Kenneth P. Johnson, 1985, Journal of Neuroimmunology.

CSF antibody to myelin basic protein. Measurement in patients with multiple sclerosis and subacute sclerosing panencephalitis.

H. Panitch, C. Hooper, K. Johnson, 1980, Archives of neurology.

Adoptive transfer of experimental allergic encephalomyelitis with activated spleen cells: comparison of in vitro activation by concanavalin a and myelin basic protein.

H. Panitch, 1980, Cellular immunology.

Antibodies to Myelin Basic Protein in Cerebrospinal Fluid of Patients with Multiple Sclerosis

D. Hafler, H. Panitch, K. Johnson, 1980 .

Systemic α-Interferon in Multiple Sclerosis: Long-term Patient Follow-up

H. Panitch, 1987 .

Interferons in multiple sclerosis. A review of the evidence.

H. Panitch, 1992, Drugs.

A neurologic rating scale (NRS) for use in multiple sclerosis

R. Knobler, G. Rice, H. Panitch, 1984, Neurology.

Experimental allergic encephalomyelitis: enhancement of cell-mediated transfer by concanavalin A.

D. McFarlin, H. Panitch, 1977, Journal of immunology.

VIRUS-INDUCED CELL-MEDIATED IMMUNOPATHOLOGICAL DISEASE

H. Panitch, A. Monjan, N. Nathanson, 1975 .

Myelopathic neurosarcoidosis

H. Panitch, D. Kristt, M. Sauter, 1991, Neurology.

Serial combination therapy: is immune modulation in multiple sclerosis enhanced by initial immune suppression?

D. Arnold, A. Bar-Or, J. Oger, 2009, Multiple sclerosis.

Pathogenesis of visna. II. Effect of immunosuppression upon early central nervous system lesions.

H. Panitch, G. Georgsson, N. Nathanson, 1976, Laboratory investigation; a journal of technical methods and pathology.

Experimental herpes simplex encephalitis. Treatment with pyrimidine nucleosides.

H. Panitch, J. Baringer, 1973, Archives of neurology.

Alexia without agraphia in multiple sclerosis: case report with magnetic resonance imaging localization

H. Panitch, Y. Mao-Draayer, 2004, Multiple sclerosis.

Effect of antiviral agents on replication of herpes simplex virus type 1 in brain cultures

R. Dix, H. Panitch, L. Pulliam, 1986, Antimicrobial Agents and Chemotherapy.

Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group.

Jeffrey A. Cohen, R. Schiffer, L. Weiner, 1995, Neurology.

Results of a randomized, double-blind, placebo-controlled, crossover trial

C. Bever, H. Panitch, O. Khan, 2012 .

Treatment of multiple sclerosis with gamma interferon

R. Hirsch, H. Panitch, J. Schindler, 1987, Neurology.

Investigational drug therapies for treatment of multiple sclerosis

H. Panitch, 1996, Multiple sclerosis.

Treatment of walking impairment in multiple sclerosis: an unmet need for a disease-specific disability

H. Panitch, A. Applebee, 2011, Expert opinion on pharmacotherapy.

Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial

A. Evans, M. Filippi, C. Pozzilli, 2000, Nature Medicine.

Subacute sclerosing panencephalitis: remission after treatment with intraventricular interferon

K. Cantell, H. Panitch, F. Norris, 1986, Neurology.

Brain stem tumors of childhood and adolescence.

H. Panitch, B. Berg, 1970, American journal of diseases of children.

Interferons in Multiple Sclerosis

H. Panitch, 1992, Drugs.

Clinical trials of interferons in multiple sclerosis what have we learned?

C. Bever, H. Panitch, 1993, Journal of Neuroimmunology.

The association of cervical spondylosis and multiple sclerosis.

H. Panitch, D. Rigamonti, P. Fishman, 1992, Surgical neurology.

Systemic alpha‐interferon therapy of multiple sclerosis

T. Merigan, R. Knobler, G. Rice, 1984, Neurology.

Relation between humoral pathological changes in multiple sclerosis and response to therapeutic plasma exchange

B. Weinshenker, C. Lucchinetti, W. Brück, 2005, The Lancet.

Cytokine changes during interferon-beta therapy in multiple sclerosis: Correlations with interferon dose and MRI response

H. Panitch, G. Francis, S. Dhib-jalbut, 2007, Journal of Neuroimmunology.

Leukocytes from multiple sclerosis patients respond to α- and γ-interferons

H. Panitch, R. Kamin-Lewis, K. Johnson, 1985, Journal of Neuroimmunology.

Decreased interferon synthesis and responsiveness to interferon by leukocytes from multiple sclerosis patients given natural alpha interferon.

T. Merigan, H. Panitch, R. Kamin-Lewis, 1984, Journal of interferon research.

Glatiramer Acetate or Interferon-β for Multiple Sclerosis?

H. Panitch, R. Milo, 1999 .

Additive effects of copolymer-1 and interferon β-1b on the immune response to myelin basic protein

H. Panitch, R. Milo, 1995, Journal of Neuroimmunology.

Early stage and long term treatment of multiple sclerosis with interferon-β

H. Panitch, A. Applebee, 2009, Biologics : targets & therapy.

Benefits of high-dose, high-frequency interferon beta-1a in relapsing–remitting multiple sclerosis are sustained to 16 months: Final comparative results of the EVIDENCE trial

D. Goodin, David K.B. Li, H. Panitch, 2005, Journal of the Neurological Sciences.

Therapeutic use of dextromethorphan: Key learnings from treatment of pseudobulbar affect

H. Panitch, Ariel Miller, 2007, Journal of the Neurological Sciences.

Continuous long-term immunomodulatory therapy in relapsing multiple sclerosis: results from the 15-year analysis of the US prospective open-label study of glatiramer acetate

J. Wolinsky, H. Panitch, A. Goodman, 2010, Multiple sclerosis.

Extended use of glatiramer acetate (Copaxone) is well tolerated and maintains its clinical effect on multiple sclerosis relapse rate and degree of disability

J S Wolinsky, R. Schiffer, L. Weiner, 1998, Neurology.

Effect of Propranolol and IFN-β on the Induction of MHC Class II Expression and Cytokine Production by IFN-γ in THP-1 Human Monocytic Cells

C. Bever, H. Panitch, Q. Li, 1998 .

Reflex epilepsy evoked by decision making.

H. Panitch, F. M. Forster, R. E. Paulsen, 1975, Archives of neurology.

Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.

H. Panitch, S. Schwid, 2007, Clinical therapeutics.

Systemic recombinant human interferon-beta treatment of relapsing-remitting multiple sclerosis: pilot study analysis and six-year follow-up.

R. Knobler, H. Panitch, F. Lublin, 1993, Journal of interferon research.

Glatiramer acetate after induction therapy with mitoxantrone in relapsing multiple sclerosis

D. Arnold, A. Bar-Or, M. Freedman, 2008, Multiple sclerosis.

Randomized, comparative study of interferon &bgr;-1a treatment regimens in MS: The EVIDENCE Trial

D. Goodin, B. Weinshenker, David K.B. Li, 2002 .

Activated suppressor cells inhibit synthesis of interferonγ in patients with multiple sclerosis and normal subjects

H. Panitch, K. Johnson, J. S. Folus, 1991, Journal of Neuroimmunology.

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

C. Bever, H. Panitch, O. Khan, 1996, Neurology.

Systemic Recombinant α-2Interferon Therapy in Relapsing Multiple Sclerosis

R. Hirsch, H. Panitch, C. Koski, 1986 .

Ethics of placebo-controlled clinical trials in multiple sclerosis

G R Cutter, A J Thompson, F Barkhof, 2008, Neurology.

Combination therapy in multiple sclerosis

H. Panitch, R. Milo, 2011, Journal of Neuroimmunology.

The effects of 4‐aminopyridine in multiple sclerosis patients

C. Bever, H. Panitch, P. A. Anderson, 1994, Neurology.

Clinical Trial of Natural Alpha Interferon in Multiple Sclerosis a

T. Merigan, R. Knobler, G. Rice, 1984, Annals of the New York Academy of Sciences.

Preliminary trial of 3,4‐diaminopyridine in patients with multiple sclerosis

C. Bever, H. Panitch, J. Leslie, 1990, Annals of neurology.

T-lymphocyte subsets in cerebrospinal fluid in multiple sclerosis.

H. Panitch, G. Francis, 1982, The New England journal of medicine.

Demyelinating disease after neurologically complicated primary Epstein‐Barr virus infection

D. McFarlin, H. Panitch, P. Bray, 1992, Neurology.

Induction of recurrent experimental allergic encephalomyelitis with myelin basic protein

H. Panitch, C. Ciccone, 1981, Annals of neurology.

Concurrence of multiple sclerosis and brain tumor

H. Panitch, O. Khan, E. Aldrich, 1997, Neurology.

The effect of interferon-beta on mouse neural progenitor cell survival and differentiation.

H. Panitch, Y. Mao-Draayer, J. Soltys, 2009, Biochemical and biophysical research communications.

Gamma‐interferon induction in patients with chronic progressive MS

C. Bever, D. McFarlin, H. Panitch, 1991, Neurology.

A prospective open-label study of glatiramer acetate: over a decade of continuous use in multiple sclerosis patients

J. Wolinsky, H. Panitch, C. Ford, 2006, Multiple sclerosis.

Enhanced benefit of increasing interferon beta-1a dose and frequency in relapsing multiple sclerosis: the EVIDENCE Study.

D. Goodin, David K.B. Li, H. Panitch, 2005, Archives of neurology.

Serial immunological studies in multiple sclerosis patients treated systemically with human alpha interferon

T. Merigan, H. Panitch, G. Francis, 1985, Annals of neurology.

Nuclear magnetic resonance imaging in multiple sclerosis.

L Kaufman, M J Aminoff, L. Kaufman, 1983, Annals of neurology.

Baseline MRI characteristics of patients at high risk for multiple sclerosis: results from the CHAMPS trial

Michael Wall, D. Barlett, J. Herbert, 2002, Multiple sclerosis.

Selecting relapsing remitting multiple sclerosis patients for treatment: the case for early treatment

R. Herndon, R. Rudick, H. Panitch, 1999, Journal of Neuroimmunology.

Interferon-β-1a induces increases in vascular cell adhesion molecule: implications for its mode of action in multiple sclerosis

P. Calabresi, C. Bever, H. Panitch, 2005, Journal of Neuroimmunology.

A phase I clinical trial of human recombinant beta interferon in relapsing-remitting multiple sclerosis

R. Knobler, H. Panitch, J. R. Wilson, 1987, Journal of Neuroimmunology.

Predictors of short-term disease activity following a first clinical demyelinating event: analysis of the CHAMPS placebo groupy

Jeffrey A. Cohen, S. Cole, D. Arnold, 2002, Multiple sclerosis.

Effects of experimental recombinant interferons on multiple sclerosis.

H. Panitch, K. Johnson, 1989, Transactions of the American Clinical and Climatological Association.

The treatment of subacute sclerosing panencephalitis with interferon: a case report

K. Cantell, H. Panitch, F. Norris, 1986, Journal of Neurology.

Diagnosing MS: Comparing Poser and McDonald Criteria

H. Panitch, 2004 .

Increased cathepsin B activity in peripheral blood mononuclear cells of multiple sclerosis patients

C. Bever, H. Panitch, K. Johnson, 1994, Neurology.

IMMUNOLOGICAL STUDIES IN PATIENTS WITH ACQUIRED IMMUNE DEFICIENCY SYNDROME

H. Panitch, W. Lipkin, C. Hooper, 1984, Annals of the New York Academy of Sciences.